Calculate the half maximal inhibitory concentration (IC50) for each compound used in a SARS-CoV-2 study
Version 1

Workflow Type: Jupyter
Stable

Summary

This notebook demonstrates how to retrieve metadata associated to the paper A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection and available in IDR at idr0094-ellinger-sarscov2. Over 300 compounds were used in this investigation. This notebook allows the user to calculate the half maximal inhibitory concentration (IC50) for each compound. IC50 is a measure of the potency of a substance in inhibiting a specific biological or biochemical function. IC50 is a quantitative measure that indicates how much of a particular inhibitory substance (e.g. drug) is needed to inhibit, in vitro, a given biological process or biological component by 50%. User can download the IC50 for each compound used in that study

The notebook can be launched in My Binder.

A shiny app is also available for dynamic plotting of the IC50 curve for each compound. This R shiny app can be launched in My Binder

Inputs

Parameters needed to configure the workflow:

screenId: Identifier of a screen in IDR.

Ouputs

Output file generated:

ic50.csv: Comma separate value file containing the IC50 for each compound.

Version History

Version 1 (earliest) Created 16th Nov 2021 at 10:19 by Jean-Marie Burel

Added/updated 1 files


Open master 8666d70
help Creators and Submitter
Creator
Additional credit

Andrea Zaliani

Submitter
Discussion Channel
Citation
BUREL, J. E. A. N.-M. A. R. I. E. (2021). Calculate the half maximal inhibitory concentration (IC50) for each compound used in a SARS-CoV-2 study. WorkflowHub. https://doi.org/10.48546/WORKFLOWHUB.WORKFLOW.238.1
Activity

Views: 488   Downloads: 13

Created: 16th Nov 2021 at 10:19

Last used: 25th Jun 2022 at 02:27

help Tags
help Attributions

None

help Collections
Total size: 228 KB
Powered by
(v.1.12.0)
Copyright © 2008 - 2022 The University of Manchester and HITS gGmbH

By continuing to use this site you agree to the use of cookies